Get the Stockscreener App
212.91
0.67%
1.42
After Hours:
212.93
0.02
+0.01%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $212.91, with a volume of 1.11M.
It is up +0.67% in the last 24 hours and down -5.26% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$211.49
Open:
$209
24h Volume:
1.11M
Relative Volume:
1.09
Market Cap:
$31.51B
Revenue:
$4.93B
Net Income/Loss:
$1.25B
P/E Ratio:
25.14
EPS:
8.47
Net Cash Flow:
$1.38B
1W Performance:
+1.12%
1M Performance:
-5.26%
6M Performance:
-11.14%
1Y Performance:
+22.48%
1-Day Range:
$202.00
$214.32
1-Week Range:
$202.00
$217.38
52-Week Range:
$176.33
$263.05
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Fund Update: QRG CAPITAL MANAGEMENT, INC. added 47,913 shares of RESMED ($RMD) to their portfolio - Nasdaq
What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings - Yahoo Finance
ResMed Pushes Forward With Strong Growth In Sleep Apnea Market - Finimize
ResMed to Maintain Dominant Sleep Apnea Device Market Share, Expected to Deliver Net Cash Balance Sheet, Jarden Research Says - marketscreener.com
Mizuho Securities Adjusts ResMed Price Target to $265 From $280, Maintains Outperform Rating - marketscreener.com
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Jarden Research Adjusts Resmed's Price Target to AU$39.97 from AU$41.48, Keeps at Overweight - MarketScreener
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo
Earnings Preview: What to Expect From ResMed’s Report - TradingView
ResMed (RMD) Placed on Citi's 90-Day Downside Catalyst Watch | R - GuruFocus
Positive Outlook for Resmed Inc: Buy Rating Despite Short-Term Challenges - TipRanks
ResMed CFO Brett Sandercock sells $215,580 in stock By Investing.com - Investing.com Canada
Sonic and ResMed rejoin the Buy List - Intelligent Investor
ResMed CFO Brett Sandercock sells $215,580 in stock - Investing.com Australia
Why I'm taking a closer look at ResMed shares - The Motley Fool Australia
ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says - MarketScreener
ResMed CEO Michael Farrell sells $1.68 million in stock By Investing.com - Investing.com India
Resmed Insider Sold Shares Worth $1,680,699, According to a Recent SEC Filing - MarketScreener
ResMed CEO Michael Farrell sells $1.68 million in stock - Investing.com
ResMed CFO Sells Shares - MarketScreener
ResMed Inc. Officer Plans to Sell Shares Under Rule 144 - TipRanks
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength? - Nasdaq
Resmed launches HSAT across US - HME News
ResMed Inc Chairman Emeritus Adjusts Stock Holdings - TipRanks
ResMed Inc. (RMD): A Bull Case Theory - MSN
ResMed director Peter Farrell sells $439,480 in stock By Investing.com - Investing.com South Africa
ResMed director Peter Farrell sells $439,480 in stock - Investing.com
Resmed debuts wearable, at-home sleep apnea test - Fierce Biotech
RMD Stock Benefits From the Launch of NightOwl Across US - TradingView
Should I buy Fisher & Paykel or ResMed shares? - MSN
ResMed’s global general counsel sells $14,263 in stock By Investing.com - Investing.com Canada
ResMed Launches Home Sleep Apnea Test Across US; Shares Fall 3% - MarketScreener
ResMed Inc Reports Changes in CDI and Securities Issuance - TipRanks
ResMed Inc’s General Counsel Reports Stock Transaction - TipRanks
ResMed launches at-home sleep apnea test - MassDevice
ResMed’s global general counsel sells $14,263 in stock - Investing.com India
ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US - Yahoo Finance
Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 50% gain - simplywall.st
Resmed Launches NightOwl Home Sleep Apnea Test - Medical Product Outsourcing
Game-Changing Sleep Apnea Test: Resmed's Tiny Device Tackles 80% Diagnosis Gap - Stock Titan
Resmed To Report Third Quarter Fiscal 2025 Earnings On April 23, 2025 - MarketScreener
ResMed Director Announces Sale of Common Shares - TipRanks
Resmed to Announce Q3 Fiscal 2025 Earnings - TipRanks
Resmed Inc. (RMD): Jim Cramer Says He Likes This Sleep Apnea Treatment Stock - Insider Monkey
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 - Bluefield Daily Telegraph
ResMed Inc. (NYSE:RMD) Stake Increased by NEOS Investment Management LLC - MarketBeat
Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well” - Insider Monkey
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Resmed Inc Stock (RMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chief Executive Officer |
Apr 07 '25 |
Option Exercise |
101.64 |
8,009 |
814,035 |
463,482 |
| Farrell Michael J. | Chief Executive Officer |
Apr 07 '25 |
Sale |
209.85 |
8,009 |
1,680,699 |
455,472 |
0.53%
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):